Theratechnologies Inc
TSX:TH
Intrinsic Value
Theratechnologies, Inc. is a pharmaceutical company. [ Read More ]
The intrinsic value of one TH stock under the Base Case scenario is 9.31 CAD. Compared to the current market price of 2.23 CAD, Theratechnologies Inc is Undervalued by 76%.
Valuation Backtest
Theratechnologies Inc
Run backtest to discover the historical profit from buying and selling TH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Theratechnologies Inc's business.
What risks and challenges
does Theratechnologies Inc face in the near future?
Summarize the latest earnings report
of Theratechnologies Inc.
Provide P/E
for Theratechnologies Inc and its competitors.
Balance Sheet Decomposition
Theratechnologies Inc
Current Assets | 40.6m |
Cash & Short-Term Investments | 22.9m |
Receivables | 9.1m |
Other Current Assets | 8.6m |
Non-Current Assets | 16.1m |
PP&E | 2.2m |
Intangibles | 12.9m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 97.7m |
Accounts Payable | 30.5m |
Other Current Liabilities | 67.2m |
Non-Current Liabilities | 734k |
Long-Term Debt | 684k |
Other Non-Current Liabilities | 50k |
Earnings Waterfall
Theratechnologies Inc
Revenue
|
79.7m
USD
|
Cost of Revenue
|
-20.5m
USD
|
Gross Profit
|
59.3m
USD
|
Operating Expenses
|
-78.3m
USD
|
Operating Income
|
-19m
USD
|
Other Expenses
|
-10.1m
USD
|
Net Income
|
-29.1m
USD
|
Free Cash Flow Analysis
Theratechnologies Inc
What is Free Cash Flow?
TH Profitability Score
Profitability Due Diligence
Theratechnologies Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Theratechnologies Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
TH Solvency Score
Solvency Due Diligence
Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Theratechnologies Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TH Price Targets Summary
Theratechnologies Inc
According to Wall Street analysts, the average 1-year price target for TH is 6.55 CAD with a low forecast of 4.9 CAD and a high forecast of 8.4 CAD.
Shareholder Return
TH Price
Theratechnologies Inc
Average Annual Return | -28.97% |
Standard Deviation of Annual Returns | 35.18% |
Max Drawdown | -96% |
Market Capitalization | 102.5m CAD |
Shares Outstanding | 45 980 000 |
Percentage of Shares Shorted | 0.03% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
Contact
IPO
Employees
Officers
The intrinsic value of one TH stock under the Base Case scenario is 9.31 CAD.
Compared to the current market price of 2.23 CAD, Theratechnologies Inc is Undervalued by 76%.